APO Research
Talk to an analyst

APO RESEARCH · REPORT

Peptide and Oligonucleotide Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Peptide and Oligonucleotide Drugs Market Analysis and Forecast 2026-2032

29 December 2025205 pages

Choose your research edition.

Industry ResearchPeptide and Oligonucleotide Drugs Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Peptide and Oligonucleotide Drugs Industry Growth and Trends Forecast to 2032117 pages · $3,450 USDMarket StructureGlobal Peptide and Oligonucleotide Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peptide and Oligonucleotide Drugs Market Outlook and Growth Opportunities 2026202 pages · $4,250 USDMarket Analysis & ForecastGlobal Peptide and Oligonucleotide Drugs Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

The global Peptide and Oligonucleotide Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Peptide and Oligonucleotide Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Peptide and Oligonucleotide Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Peptide and Oligonucleotide Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Peptide and Oligonucleotide Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Peptide and Oligonucleotide Drugs include Takeda, Sanofi, Novartis, Roche, Lilly, SciClone Pharmaceuticals, Sarepta Therapeutics, Nippon Shinyaku and Moderna, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Peptide and Oligonucleotide Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Peptide and Oligonucleotide Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Peptide and Oligonucleotide Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Peptide and Oligonucleotide Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Peptide and Oligonucleotide Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Peptide and Oligonucleotide Drugs sales, projected growth trends, production technology, application and end-user industry.

Peptide and Oligonucleotide Drugs Segment by Company

Takeda

Sanofi

Novartis

Roche

Lilly

SciClone Pharmaceuticals

Sarepta Therapeutics

Nippon Shinyaku

Moderna

MiNA Therapeutics

Merck Serono

Ipsen PHarma Biotech

Ionis

Ferring Pharmaceuticals

BioNTech

AstraZeneca

Asahi Kasei

Alnylam

Peptide and Oligonucleotide Drugs Segment by Type

Oligonucleotide Drugs

Peptide Drugs

Peptide and Oligonucleotide Drugs Segment by Application

Oncology Drugs

Digestive system Drugs

Immunomodulatory Drugs

Bone and Connective Tissue Types

Other

Peptide and Oligonucleotide Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide and Oligonucleotide Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peptide and Oligonucleotide Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide and Oligonucleotide Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Peptide and Oligonucleotide Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Peptide and Oligonucleotide Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Peptide and Oligonucleotide Drugs sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Peptide and Oligonucleotide Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Oligonucleotide Drugs Major Manufacturers Table 3. Peptide Drugs Major Manufacturers Table 4. Global Peptide and Oligonucleotide Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Oncology Drugs Major Manufacturers Table 6. Digestive system Drugs Major Manufacturers Table 7. Immunomodulatory Drugs Major Manufacturers Table 8. Bone and Connective Tissue Types Major Manufacturers Table 9. Other Major Manufacturers Table 10. Peptide and Oligonucleotide Drugs Industry Trends Table 11. Peptide and Oligonucleotide Drugs Industry Drivers Table 12. Peptide and Oligonucleotide Drugs Industry Opportunities and Challenges Table 13. Peptide and Oligonucleotide Drugs Industry Restraints Table 14. Global Peptide and Oligonucleotide Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global Peptide and Oligonucleotide Drugs Revenue by Region (2021-2026) & (US$ Million) Table 16. Global Peptide and Oligonucleotide Drugs Revenue by Region (2027-2032) & (US$ Million) Table 17. Global Peptide and Oligonucleotide Drugs Revenue Market Share by Region (2021-2026) Table 18. Global Peptide and Oligonucleotide Drugs Revenue Market Share by Region (2027-2032) Table 19. Global Peptide and Oligonucleotide Drugs Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 20. Global Peptide and Oligonucleotide Drugs Sales by Region (2021-2026) & (K Units) Table 21. Global Peptide and Oligonucleotide Drugs Sales by Region (2027-2032) & (K Units) Table 22. Global Peptide and Oligonucleotide Drugs Sales Market Share by Region (2021-2026) Table 23. Global Peptide and Oligonucleotide Drugs Sales Market Share by Region (2027-2032) Table 24. Global Peptide and Oligonucleotide Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Peptide and Oligonucleotide Drugs Revenue Market Share by Manufacturers (2021-2026) Table 26. Global Peptide and Oligonucleotide Drugs Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Peptide and Oligonucleotide Drugs Sales Market Share by Manufacturers (2021-2026) Table 28. Global Peptide and Oligonucleotide Drugs Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 29. Global Peptide and Oligonucleotide Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global Peptide and Oligonucleotide Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global Peptide and Oligonucleotide Drugs Manufacturers, Product Type & Application Table 32. Global Peptide and Oligonucleotide Drugs Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global Peptide and Oligonucleotide Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global Peptide and Oligonucleotide Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Peptide and Oligonucleotide Drugs Revenue by Type (2021-2026) & (US$ Million) Table 37. Global Peptide and Oligonucleotide Drugs Revenue by Type (2027-2032) & (US$ Million) Table 38. Global Peptide and Oligonucleotide Drugs Revenue Market Share by Type (2021-2026) Table 39. Global Peptide and Oligonucleotide Drugs Revenue Market Share by Type (2027-2032) Table 40. Global Peptide and Oligonucleotide Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 41. Global Peptide and Oligonucleotide Drugs Sales by Type (2021-2026) & (K Units) Table 42. Global Peptide and Oligonucleotide Drugs Sales by Type (2027-2032) & (K Units) Table 43. Global Peptide and Oligonucleotide Drugs Sales Market Share by Type (2021-2026) Table 44. Global Peptide and Oligonucleotide Drugs Sales Market Share by Type (2027-2032) Table 45. Global Peptide and Oligonucleotide Drugs Price by Type (2021-2026) & (US$/Unit) Table 46. Global Peptide and Oligonucleotide Drugs Price by Type (2027-2032) & (US$/Unit) Table 47. Global Peptide and Oligonucleotide Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Peptide and Oligonucleotide Drugs Revenue by Application (2021-2026) & (US$ Million) Table 49. Global Peptide and Oligonucleotide Drugs Revenue by Application (2027-2032) & (US$ Million) Table 50. Global Peptide and Oligonucleotide Drugs Revenue Market Share by Application (2021-2026) Table 51. Global Peptide and Oligonucleotide Drugs Revenue Market Share by Application (2027-2032) Table 52. Global Peptide and Oligonucleotide Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 53. Global Peptide and Oligonucleotide Drugs Sales by Application (2021-2026) & (K Units) Table 54. Global Peptide and Oligonucleotide Drugs Sales by Application (2027-2032) & (K Units) Table 55. Global Peptide and Oligonucleotide Drugs Sales Market Share by Application (2021-2026) Table 56. Global Peptide and Oligonucleotide Drugs Sales Market Share by Application (2027-2032) Table 57. Global Peptide and Oligonucleotide Drugs Price by Application (2021-2026) & (US$/Unit) Table 58. Global Peptide and Oligonucleotide Drugs Price by Application (2027-2032) & (US$/Unit) Table 59. Takeda Company Information Table 60. Takeda Business Overview Table 61. Takeda Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 62. Takeda Peptide and Oligonucleotide Drugs Product Portfolio Table 63. Takeda Recent Development Table 64. Sanofi Company Information Table 65. Sanofi Business Overview Table 66. Sanofi Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Sanofi Peptide and Oligonucleotide Drugs Product Portfolio Table 68. Sanofi Recent Development Table 69. Novartis Company Information Table 70. Novartis Business Overview Table 71. Novartis Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Novartis Peptide and Oligonucleotide Drugs Product Portfolio Table 73. Novartis Recent Development Table 74. Roche Company Information Table 75. Roche Business Overview Table 76. Roche Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Roche Peptide and Oligonucleotide Drugs Product Portfolio Table 78. Roche Recent Development Table 79. Lilly Company Information Table 80. Lilly Business Overview Table 81. Lilly Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Lilly Peptide and Oligonucleotide Drugs Product Portfolio Table 83. Lilly Recent Development Table 84. SciClone Pharmaceuticals Company Information Table 85. SciClone Pharmaceuticals Business Overview Table 86. SciClone Pharmaceuticals Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. SciClone Pharmaceuticals Peptide and Oligonucleotide Drugs Product Portfolio Table 88. SciClone Pharmaceuticals Recent Development Table 89. Sarepta Therapeutics Company Information Table 90. Sarepta Therapeutics Business Overview Table 91. Sarepta Therapeutics Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Sarepta Therapeutics Peptide and Oligonucleotide Drugs Product Portfolio Table 93. Sarepta Therapeutics Recent Development Table 94. Nippon Shinyaku Company Information Table 95. Nippon Shinyaku Business Overview Table 96. Nippon Shinyaku Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Nippon Shinyaku Peptide and Oligonucleotide Drugs Product Portfolio Table 98. Nippon Shinyaku Recent Development Table 99. Moderna Company Information Table 100. Moderna Business Overview Table 101. Moderna Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Moderna Peptide and Oligonucleotide Drugs Product Portfolio Table 103. Moderna Recent Development Table 104. MiNA Therapeutics Company Information Table 105. MiNA Therapeutics Business Overview Table 106. MiNA Therapeutics Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. MiNA Therapeutics Peptide and Oligonucleotide Drugs Product Portfolio Table 108. MiNA Therapeutics Recent Development Table 109. Merck Serono Company Information Table 110. Merck Serono Business Overview Table 111. Merck Serono Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Merck Serono Peptide and Oligonucleotide Drugs Product Portfolio Table 113. Merck Serono Recent Development Table 114. Ipsen PHarma Biotech Company Information Table 115. Ipsen PHarma Biotech Business Overview Table 116. Ipsen PHarma Biotech Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Ipsen PHarma Biotech Peptide and Oligonucleotide Drugs Product Portfolio Table 118. Ipsen PHarma Biotech Recent Development Table 119. Ionis Company Information Table 120. Ionis Business Overview Table 121. Ionis Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Ionis Peptide and Oligonucleotide Drugs Product Portfolio Table 123. Ionis Recent Development Table 124. Ferring Pharmaceuticals Company Information Table 125. Ferring Pharmaceuticals Business Overview Table 126. Ferring Pharmaceuticals Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Ferring Pharmaceuticals Peptide and Oligonucleotide Drugs Product Portfolio Table 128. Ferring Pharmaceuticals Recent Development Table 129. BioNTech Company Information Table 130. BioNTech Business Overview Table 131. BioNTech Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. BioNTech Peptide and Oligonucleotide Drugs Product Portfolio Table 133. BioNTech Recent Development Table 134. AstraZeneca Company Information Table 135. AstraZeneca Business Overview Table 136. AstraZeneca Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. AstraZeneca Peptide and Oligonucleotide Drugs Product Portfolio Table 138. AstraZeneca Recent Development Table 139. Asahi Kasei Company Information Table 140. Asahi Kasei Business Overview Table 141. Asahi Kasei Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. Asahi Kasei Peptide and Oligonucleotide Drugs Product Portfolio Table 143. Asahi Kasei Recent Development Table 144. Alnylam Company Information Table 145. Alnylam Business Overview Table 146. Alnylam Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 147. Alnylam Peptide and Oligonucleotide Drugs Product Portfolio Table 148. Alnylam Recent Development Table 149. North America Peptide and Oligonucleotide Drugs Revenue by Type (2021-2026) & (US$ Million) Table 150. North America Peptide and Oligonucleotide Drugs Revenue by Type (2027-2032) & (US$ Million) Table 151. North America Peptide and Oligonucleotide Drugs Sales by Type (2021-2026) & (K Units) Table 152. North America Peptide and Oligonucleotide Drugs Sales by Type (2027-2032) & (K Units) Table 153. North America Peptide and Oligonucleotide Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 154. North America Peptide and Oligonucleotide Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 155. North America Peptide and Oligonucleotide Drugs Revenue by Application (2021-2026) & (US$ Million) Table 156. North America Peptide and Oligonucleotide Drugs Revenue by Application (2027-2032) & (US$ Million) Table 157. North America Peptide and Oligonucleotide Drugs Sales by Application (2021-2026) & (K Units) Table 158. North America Peptide and Oligonucleotide Drugs Sales by Application (2027-2032) & (K Units) Table 159. North America Peptide and Oligonucleotide Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 160. North America Peptide and Oligonucleotide Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 161. North America Peptide and Oligonucleotide Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 162. North America Peptide and Oligonucleotide Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 163. North America Peptide and Oligonucleotide Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 164. North America Peptide and Oligonucleotide Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 165. North America Peptide and Oligonucleotide Drugs Sales by Country (2021-2026) & (K Units) Table 166. North America Peptide and Oligonucleotide Drugs Sales by Country (2027-2032) & (K Units) Table 167. North America Peptide and Oligonucleotide Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 168. North America Peptide and Oligonucleotide Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 169. United States Peptide and Oligonucleotide Drugs Revenue (2021-2032) & (US$ Million) Table 170. Canada Peptide and Oligonucleotide Drugs Revenue (2021-2032) & (US$ Million) Table 171. Mexico Peptide and Oligonucleotide Drugs Revenue (2021-2032) & (US$ Million) Table 172. Europe Peptide and Oligonucleotide Drugs Revenue by Type (2021-2026) & (US$ Million) Table 173. Europe Peptide and Oligonucleotide Drugs Revenue by Type (2027-2032) & (US$ Million) Table 174. Europe Peptide and Oligonucleotide Drugs Sales by Type (2021-2026) & (K Units) Table 175. Europe Peptide and Oligonucleotide Drugs Sales by Type (2027-2032) & (K Units) Table 176. Europe Peptide and Oligonucleotide Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 177. Europe Peptide and Oligonucleotide Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 178. Europe Peptide and Oligonucleotide Drugs Revenue by Application (2021-2026) & (US$ Million) Table 179. Europe Peptide and Oligonucleotide Drugs Revenue by Application (2027-2032) & (US$ Million) Table 180. Europe Peptide and Oligonucleotide Drugs Sales by Application (2021-2026) & (K Units) Table 181. Europe Peptide and Oligonucleotide Drugs Sales by Application (2027-2032) & (K Units) Table 182. Europe Peptide and Oligonucleotide Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 183. Europe Peptide and Oligonucleotide Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 184. Europe Peptide and Oligonucleotide Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 185. Europe Peptide and Oligonucleotide Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 186. Europe Peptide and Oligonucleotide Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 187. Europe Peptide and Oligonucleotide Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 188. Europe Peptide and Oligonucleotide Drugs Sales by Country (2021-2026) & (K Units) Table 189. Europe Peptide and Oligonucleotide Drugs Sales by Country (2027-2032) & (K Units) Table 190. Europe Peptide and Oligonucleotide Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 191. Europe Peptide and Oligonucleotide Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 192. Germany Peptide and Oligonucleotide Drugs Revenue (2021-2032) & (US$ Million) Table 193. France Peptide and Oligonucleotide Drugs Revenue (2021-2032) & (US$ Million) Table 194. U.K. Peptide and Oligonucleotide Drugs Revenue (2021-2032) & (US$ Million) Table 195. Italy Peptide and Oligonucleotide Drugs Revenue (2021-2032) & (US$ Million) Table 196. Russia Peptide and Oligonucleotide Drugs Revenue (2021-2032) & (US$ Million) Table 197. Spain Peptide and Oligonucleotide Drugs Revenue (2021-2032) & (US$ Million) Table 198. Netherlands Peptide and Oligonucleotide Drugs Revenue (2021-2032) & (US$ Million) Table 199. Switzerland Peptide and Oligonucleotide Drugs Revenue (2021-2032) & (US$ Million) Table 200. Sweden Peptide and Oligonucleotide Drugs Revenue (2021-2032) & (US$ Million) Table 201. Poland Peptide and Oligonucleotide Drugs Revenue (2021-2032) & (US$ Million) Table 202. China Peptide and Oligonucleotide Drugs Revenue by Type (2021-2026) & (US$ Million) Table 203. China Peptide and Oligonucleotide Drugs Revenue by Type (2027-2032) & (US$ Million) Table 204. China Peptide and Oligonucleotide Drugs Sales by Type (2021-2026) & (K Units) Table 205. China Peptide and Oligonucleotide Drugs Sales by Type (2027-2032) & (K Units) Table 206. China Peptide and Oligonucleotide Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 207. China Peptide and Oligonucleotide Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 208. China Peptide and Oligonucleotide Drugs Revenue by Application (2021-2026) & (US$ Million) Table 209. China Peptide and Oligonucleotide Drugs Revenue by Application (2027-2032) & (US$ Million) Table 210. China Peptide and Oligonucleotide Drugs Sales by Application (2021-2026) & (K Units) Table 211. China Peptide and Oligonucleotide Drugs Sales by Application (2027-2032) & (K Units) Table 212. China Peptide and Oligonucleotide Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 213. China Peptide and Oligonucleotide Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 214. Asia Peptide and Oligonucleotide Drugs Revenue by Type (2021-2026) & (US$ Million) Table 215. Asia Peptide and Oligonucleotide Drugs Revenue by Type (2027-2032) & (US$ Million) Table 216. Asia Peptide and Oligonucleotide Drugs Sales by Type (2021-2026) & (K Units) Table 217. Asia Peptide and Oligonucleotide Drugs Sales by Type (2027-2032) & (K Units) Table 218. Asia Peptide and Oligonucleotide Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 219. Asia Peptide and Oligonucleotide Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 220. Asia Peptide and Oligonucleotide Drugs Revenue by Application (2021-2026) & (US$ Million) Table 221. Asia Peptide and Oligonucleotide Drugs Revenue by Application (2027-2032) & (US$ Million) Table 222. Asia Peptide and Oligonucleotide Drugs Sales by Application (2021-2026) & (K Units) Table 223. Asia Peptide and Oligonucleotide Drugs Sales by Application (2027-2032) & (K Units) Table 224. Asia Peptide and Oligonucleotide Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 225. Asia Peptide and Oligonucleotide Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 226. Asia Peptide and Oligonucleotide Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 227. Asia Peptide and Oligonucleotide Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 228. Asia Peptide and Oligonucleotide Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 229. Asia Peptide and Oligonucleotide Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 230. Asia Peptide and Oligonucleotide Drugs Sales by Country (2021-2026) & (K Units) Table 231. Asia Peptide and Oligonucleotide Drugs Sales by Country (2027-2032) & (K Units) Table 232. Asia Peptide and Oligonucleotide Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 233. Asia Peptide and Oligonucleotide Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 234. Japan Peptide and Oligonucleotide Drugs Revenue (2021-2032) & (US$ Million) Table 235. South Korea Peptide and Oligonucleotide Drugs Revenue (2021-2032) & (US$ Million) Table 236. India Peptide and Oligonucleotide Drugs Revenue (2021-2032) & (US$ Million) Table 237. Australia Peptide and Oligonucleotide Drugs Revenue (2021-2032) & (US$ Million) Table 238. Taiwan Peptide and Oligonucleotide Drugs Revenue (2021-2032) & (US$ Million) Table 239. Southeast Asia Peptide and Oligonucleotide Drugs Revenue (2021-2032) & (US$ Million) Table 240. SAMEA Peptide and Oligonucleotide Drugs Revenue by Type (2021-2026) & (US$ Million) Table 241. SAMEA Peptide and Oligonucleotide Drugs Revenue by Type (2027-2032) & (US$ Million) Table 242. SAMEA Peptide and Oligonucleotide Drugs Sales by Type (2021-2026) & (K Units) Table 243. SAMEA Peptide and Oligonucleotide Drugs Sales by Type (2027-2032) & (K Units) Table 244. SAMEA Peptide and Oligonucleotide Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 245. SAMEA Peptide and Oligonucleotide Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 246. SAMEA Peptide and Oligonucleotide Drugs Revenue by Application (2021-2026) & (US$ Million) Table 247. SAMEA Peptide and Oligonucleotide Drugs Revenue by Application (2027-2032) & (US$ Million) Table 248. SAMEA Peptide and Oligonucleotide Drugs Sales by Application (2021-2026) & (K Units) Table 249. SAMEA Peptide and Oligonucleotide Drugs Sales by Application (2027-2032) & (K Units) Table 250. SAMEA Peptide and Oligonucleotide Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 251. SAMEA Peptide and Oligonucleotide Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 252. SAMEA Peptide and Oligonucleotide Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 253. SAMEA Peptide and Oligonucleotide Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 254. SAMEA Peptide and Oligonucleotide Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 255. SAMEA Peptide and Oligonucleotide Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 256. SAMEA Peptide and Oligonucleotide Drugs Sales by Country (2021-2026) & (K Units) Table 257. SAMEA Peptide and Oligonucleotide Drugs Sales by Country (2027-2032) & (K Units) Table 258. SAMEA Peptide and Oligonucleotide Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 259. SAMEA Peptide and Oligonucleotide Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 260. Brazil Peptide and Oligonucleotide Drugs Revenue (2021-2032) & (US$ Million) Table 261. Argentina Peptide and Oligonucleotide Drugs Revenue (2021-2032) & (US$ Million) Table 262. Chile Peptide and Oligonucleotide Drugs Revenue (2021-2032) & (US$ Million) Table 263. Colombia Peptide and Oligonucleotide Drugs Revenue (2021-2032) & (US$ Million) Table 264. Peru Peptide and Oligonucleotide Drugs Revenue (2021-2032) & (US$ Million) Table 265. Saudi Arabia Peptide and Oligonucleotide Drugs Revenue (2021-2032) & (US$ Million) Table 266. Israel Peptide and Oligonucleotide Drugs Revenue (2021-2032) & (US$ Million) Table 267. UAE Peptide and Oligonucleotide Drugs Revenue (2021-2032) & (US$ Million) Table 268. Turkey Peptide and Oligonucleotide Drugs Revenue (2021-2032) & (US$ Million) Table 269. Iran Peptide and Oligonucleotide Drugs Revenue (2021-2032) & (US$ Million) Table 270. Egypt Peptide and Oligonucleotide Drugs Revenue (2021-2032) & (US$ Million) Table 271. Key Raw Materials Table 272. Raw Materials Key Suppliers Table 273. Peptide and Oligonucleotide Drugs Distributors List Table 274. Peptide and Oligonucleotide Drugs Customers List Table 275. Research Programs/Design for This Report Table 276. Authors List of This Report Table 277. Secondary Sources Table 278. Primary Sources List of Figures Figure 1. Peptide and Oligonucleotide Drugs Image Figure 2. Global Peptide and Oligonucleotide Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Peptide and Oligonucleotide Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Oligonucleotide Drugs Image Figure 5. Peptide Drugs Image Figure 6. Global Peptide and Oligonucleotide Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Peptide and Oligonucleotide Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 8. Oncology Drugs Image Figure 9. Digestive system Drugs Image Figure 10. Immunomodulatory Drugs Image Figure 11. Bone and Connective Tissue Types Image Figure 12. Other Image Figure 13. Global Peptide and Oligonucleotide Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Peptide and Oligonucleotide Drugs Revenue (2021-2032) & (US$ Million) Figure 15. Global Peptide and Oligonucleotide Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global Peptide and Oligonucleotide Drugs Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global Peptide and Oligonucleotide Drugs Revenue Market Share by Region (2021-2032) Figure 18. Global Peptide and Oligonucleotide Drugs Sales (2021-2032) & (K Units) Figure 19. Global Peptide and Oligonucleotide Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 20. Global Peptide and Oligonucleotide Drugs Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico Peptide and Oligonucleotide Drugs Sales YoY (2021-2032) & (K Units) Figure 22. Europe Peptide and Oligonucleotide Drugs Sales YoY (2021-2032) & (K Units) Figure 23. China Peptide and Oligonucleotide Drugs Sales YoY (2021-2032) & (K Units) Figure 24. Asia (Excluding China) Peptide and Oligonucleotide Drugs Sales YoY (2021-2032) & (K Units) Figure 25. South America, Middle East and Africa Peptide and Oligonucleotide Drugs Sales YoY (2021-2032) & (K Units) Figure 26. Global Peptide and Oligonucleotide Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global Peptide and Oligonucleotide Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global Peptide and Oligonucleotide Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Peptide and Oligonucleotide Drugs Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Peptide and Oligonucleotide Drugs Revenue Market Share by Type (2021-2032) Figure 32. Global Peptide and Oligonucleotide Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 33. Global Peptide and Oligonucleotide Drugs Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Peptide and Oligonucleotide Drugs Sales Market Share by Type (2021-2032) Figure 35. Global Peptide and Oligonucleotide Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global Peptide and Oligonucleotide Drugs Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Peptide and Oligonucleotide Drugs Revenue Market Share by Application (2021-2032) Figure 38. Global Peptide and Oligonucleotide Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 39. Global Peptide and Oligonucleotide Drugs Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Peptide and Oligonucleotide Drugs Sales Market Share by Application (2021-2032) Figure 41. North America Peptide and Oligonucleotide Drugs Revenue Share by Type (2021-2032) Figure 42. North America Peptide and Oligonucleotide Drugs Sales Share by Type (2021-2032) Figure 43. North America Peptide and Oligonucleotide Drugs Revenue Share by Application (2021-2032) Figure 44. North America Peptide and Oligonucleotide Drugs Sales Share by Application (2021-2032) Figure 45. North America Peptide and Oligonucleotide Drugs Revenue Share by Country (2021-2032) Figure 46. North America Peptide and Oligonucleotide Drugs Sales Share by Country (2021-2032) Figure 47. Europe Peptide and Oligonucleotide Drugs Revenue Share by Type (2021-2032) Figure 48. Europe Peptide and Oligonucleotide Drugs Sales Share by Type (2021-2032) Figure 49. Europe Peptide and Oligonucleotide Drugs Revenue Share by Application (2021-2032) Figure 50. Europe Peptide and Oligonucleotide Drugs Sales Share by Application (2021-2032) Figure 51. Europe Peptide and Oligonucleotide Drugs Revenue Share by Country (2021-2032) Figure 52. Europe Peptide and Oligonucleotide Drugs Sales Share by Country (2021-2032) Figure 53. China Peptide and Oligonucleotide Drugs Revenue Share by Type (2021-2032) Figure 54. China Peptide and Oligonucleotide Drugs Sales Share by Type (2021-2032) Figure 55. China Peptide and Oligonucleotide Drugs Revenue Share by Application (2021-2032) Figure 56. China Peptide and Oligonucleotide Drugs Sales Share by Application (2021-2032) Figure 57. Asia Peptide and Oligonucleotide Drugs Revenue Share by Type (2021-2032) Figure 58. Asia Peptide and Oligonucleotide Drugs Sales Share by Type (2021-2032) Figure 59. Asia Peptide and Oligonucleotide Drugs Revenue Share by Application (2021-2032) Figure 60. Asia Peptide and Oligonucleotide Drugs Sales Share by Application (2021-2032) Figure 61. Asia Peptide and Oligonucleotide Drugs Revenue Share by Country (2021-2032) Figure 62. Asia Peptide and Oligonucleotide Drugs Sales Share by Country (2021-2032) Figure 63. SAMEA Peptide and Oligonucleotide Drugs Revenue Share by Type (2021-2032) Figure 64. SAMEA Peptide and Oligonucleotide Drugs Sales Share by Type (2021-2032) Figure 65. SAMEA Peptide and Oligonucleotide Drugs Revenue Share by Application (2021-2032) Figure 66. SAMEA Peptide and Oligonucleotide Drugs Sales Share by Application (2021-2032) Figure 67. SAMEA Peptide and Oligonucleotide Drugs Revenue Share by Country (2021-2032) Figure 68. SAMEA Peptide and Oligonucleotide Drugs Sales Share by Country (2021-2032) Figure 69. Peptide and Oligonucleotide Drugs Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Peptide and Oligonucleotide Drugs Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Oligonucleotide Drugs
  • Peptide Drugs
Applications
  • Oncology Drugs
  • Digestive system Drugs
  • Immunomodulatory Drugs
  • Bone and Connective Tissue Types
  • Other
Companies covered
  • Takeda
  • Sanofi
  • Novartis
  • Roche
  • Lilly
  • SciClone Pharmaceuticals
  • Sarepta Therapeutics
  • Nippon Shinyaku
  • Moderna
  • MiNA Therapeutics
  • Merck Serono
  • Ipsen PHarma Biotech
  • Ionis
  • Ferring Pharmaceuticals
  • BioNTech
  • AstraZeneca
  • Asahi Kasei
  • Alnylam

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Peptide and Oligonucleotide Drugs Market by Type
  3. 1.2.1 Global Peptide and Oligonucleotide Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Oligonucleotide Drugs
  5. 1.2.3 Peptide Drugs
  6. 1.3 Peptide and Oligonucleotide Drugs Market by Application
  7. 1.3.1 Global Peptide and Oligonucleotide Drugs Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Oncology Drugs
  9. 1.3.3 Digestive system Drugs
  10. 1.3.4 Immunomodulatory Drugs
  11. 1.3.5 Bone and Connective Tissue Types
  12. 1.3.6 Other
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Peptide and Oligonucleotide Drugs Market Dynamics
  1. 2.1 Peptide and Oligonucleotide Drugs Industry Trends
  2. 2.2 Peptide and Oligonucleotide Drugs Industry Drivers
  3. 2.3 Peptide and Oligonucleotide Drugs Industry Opportunities and Challenges
  4. 2.4 Peptide and Oligonucleotide Drugs Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Peptide and Oligonucleotide Drugs Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Peptide and Oligonucleotide Drugs Revenue by Region
  3. 3.2.1 Global Peptide and Oligonucleotide Drugs Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Peptide and Oligonucleotide Drugs Revenue by Region (2021-2026)
  5. 3.2.3 Global Peptide and Oligonucleotide Drugs Revenue by Region (2027-2032)
  6. 3.2.4 Global Peptide and Oligonucleotide Drugs Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Peptide and Oligonucleotide Drugs Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Peptide and Oligonucleotide Drugs Sales by Region
  9. 3.4.1 Global Peptide and Oligonucleotide Drugs Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Peptide and Oligonucleotide Drugs Sales by Region (2021-2026)
  11. 3.4.3 Global Peptide and Oligonucleotide Drugs Sales by Region (2027-2032)
  12. 3.4.4 Global Peptide and Oligonucleotide Drugs Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Peptide and Oligonucleotide Drugs Revenue by Manufacturers
  2. 4.1.1 Global Peptide and Oligonucleotide Drugs Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Peptide and Oligonucleotide Drugs Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Peptide and Oligonucleotide Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Peptide and Oligonucleotide Drugs Sales by Manufacturers
  6. 4.2.1 Global Peptide and Oligonucleotide Drugs Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Peptide and Oligonucleotide Drugs Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Peptide and Oligonucleotide Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Peptide and Oligonucleotide Drugs Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Peptide and Oligonucleotide Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Peptide and Oligonucleotide Drugs Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Peptide and Oligonucleotide Drugs Manufacturers, Product Type & Application
  13. 4.7 Global Peptide and Oligonucleotide Drugs Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Peptide and Oligonucleotide Drugs Market CR5 and HHI
  16. 4.8.2 2025 Peptide and Oligonucleotide Drugs Tier 1, Tier 2, and Tier 3
5 Peptide and Oligonucleotide Drugs Market by Type
  1. 5.1 Global Peptide and Oligonucleotide Drugs Revenue by Type
  2. 5.1.1 Global Peptide and Oligonucleotide Drugs Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Peptide and Oligonucleotide Drugs Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Peptide and Oligonucleotide Drugs Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Peptide and Oligonucleotide Drugs Sales by Type
  6. 5.2.1 Global Peptide and Oligonucleotide Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Peptide and Oligonucleotide Drugs Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Peptide and Oligonucleotide Drugs Sales Market Share by Type (2021-2032)
  9. 5.3 Global Peptide and Oligonucleotide Drugs Price by Type
6 Peptide and Oligonucleotide Drugs Market by Application
  1. 6.1 Global Peptide and Oligonucleotide Drugs Revenue by Application
  2. 6.1.1 Global Peptide and Oligonucleotide Drugs Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Peptide and Oligonucleotide Drugs Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Peptide and Oligonucleotide Drugs Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Peptide and Oligonucleotide Drugs Sales by Application
  6. 6.2.1 Global Peptide and Oligonucleotide Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Peptide and Oligonucleotide Drugs Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Peptide and Oligonucleotide Drugs Sales Market Share by Application (2021-2032)
  9. 6.3 Global Peptide and Oligonucleotide Drugs Price by Application
7 Company Profiles
  1. 7.1 Takeda
  2. 7.1.1 Takeda Company Information
  3. 7.1.2 Takeda Business Overview
  4. 7.1.3 Takeda Peptide and Oligonucleotide Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Takeda Peptide and Oligonucleotide Drugs Product Portfolio
  6. 7.1.5 Takeda Recent Developments
  7. 7.2 Sanofi
  8. 7.2.1 Sanofi Company Information
  9. 7.2.2 Sanofi Business Overview
  10. 7.2.3 Sanofi Peptide and Oligonucleotide Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Sanofi Peptide and Oligonucleotide Drugs Product Portfolio
  12. 7.2.5 Sanofi Recent Developments
  13. 7.3 Novartis
  14. 7.3.1 Novartis Company Information
  15. 7.3.2 Novartis Business Overview
  16. 7.3.3 Novartis Peptide and Oligonucleotide Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Novartis Peptide and Oligonucleotide Drugs Product Portfolio
  18. 7.3.5 Novartis Recent Developments
  19. 7.4 Roche
  20. 7.4.1 Roche Company Information
  21. 7.4.2 Roche Business Overview
  22. 7.4.3 Roche Peptide and Oligonucleotide Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Roche Peptide and Oligonucleotide Drugs Product Portfolio
  24. 7.4.5 Roche Recent Developments
  25. 7.5 Lilly
  26. 7.5.1 Lilly Company Information
  27. 7.5.2 Lilly Business Overview
  28. 7.5.3 Lilly Peptide and Oligonucleotide Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Lilly Peptide and Oligonucleotide Drugs Product Portfolio
  30. 7.5.5 Lilly Recent Developments
  31. 7.6 SciClone Pharmaceuticals
  32. 7.6.1 SciClone Pharmaceuticals Company Information
  33. 7.6.2 SciClone Pharmaceuticals Business Overview
  34. 7.6.3 SciClone Pharmaceuticals Peptide and Oligonucleotide Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 SciClone Pharmaceuticals Peptide and Oligonucleotide Drugs Product Portfolio
  36. 7.6.5 SciClone Pharmaceuticals Recent Developments
  37. 7.7 Sarepta Therapeutics
  38. 7.7.1 Sarepta Therapeutics Company Information
  39. 7.7.2 Sarepta Therapeutics Business Overview
  40. 7.7.3 Sarepta Therapeutics Peptide and Oligonucleotide Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Sarepta Therapeutics Peptide and Oligonucleotide Drugs Product Portfolio
  42. 7.7.5 Sarepta Therapeutics Recent Developments
  43. 7.8 Nippon Shinyaku
  44. 7.8.1 Nippon Shinyaku Company Information
  45. 7.8.2 Nippon Shinyaku Business Overview
  46. 7.8.3 Nippon Shinyaku Peptide and Oligonucleotide Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Nippon Shinyaku Peptide and Oligonucleotide Drugs Product Portfolio
  48. 7.8.5 Nippon Shinyaku Recent Developments
  49. 7.9 Moderna
  50. 7.9.1 Moderna Company Information
  51. 7.9.2 Moderna Business Overview
  52. 7.9.3 Moderna Peptide and Oligonucleotide Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Moderna Peptide and Oligonucleotide Drugs Product Portfolio
  54. 7.9.5 Moderna Recent Developments
  55. 7.10 MiNA Therapeutics
  56. 7.10.1 MiNA Therapeutics Company Information
  57. 7.10.2 MiNA Therapeutics Business Overview
  58. 7.10.3 MiNA Therapeutics Peptide and Oligonucleotide Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 MiNA Therapeutics Peptide and Oligonucleotide Drugs Product Portfolio
  60. 7.10.5 MiNA Therapeutics Recent Developments
  61. 7.11 Merck Serono
  62. 7.11.1 Merck Serono Company Information
  63. 7.11.2 Merck Serono Business Overview
  64. 7.11.3 Merck Serono Peptide and Oligonucleotide Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Merck Serono Peptide and Oligonucleotide Drugs Product Portfolio
  66. 7.11.5 Merck Serono Recent Developments
  67. 7.12 Ipsen PHarma Biotech
  68. 7.12.1 Ipsen PHarma Biotech Company Information
  69. 7.12.2 Ipsen PHarma Biotech Business Overview
  70. 7.12.3 Ipsen PHarma Biotech Peptide and Oligonucleotide Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Ipsen PHarma Biotech Peptide and Oligonucleotide Drugs Product Portfolio
  72. 7.12.5 Ipsen PHarma Biotech Recent Developments
  73. 7.13 Ionis
  74. 7.13.1 Ionis Company Information
  75. 7.13.2 Ionis Business Overview
  76. 7.13.3 Ionis Peptide and Oligonucleotide Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Ionis Peptide and Oligonucleotide Drugs Product Portfolio
  78. 7.13.5 Ionis Recent Developments
  79. 7.14 Ferring Pharmaceuticals
  80. 7.14.1 Ferring Pharmaceuticals Company Information
  81. 7.14.2 Ferring Pharmaceuticals Business Overview
  82. 7.14.3 Ferring Pharmaceuticals Peptide and Oligonucleotide Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Ferring Pharmaceuticals Peptide and Oligonucleotide Drugs Product Portfolio
  84. 7.14.5 Ferring Pharmaceuticals Recent Developments
  85. 7.15 BioNTech
  86. 7.15.1 BioNTech Company Information
  87. 7.15.2 BioNTech Business Overview
  88. 7.15.3 BioNTech Peptide and Oligonucleotide Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 BioNTech Peptide and Oligonucleotide Drugs Product Portfolio
  90. 7.15.5 BioNTech Recent Developments
  91. 7.16 AstraZeneca
  92. 7.16.1 AstraZeneca Company Information
  93. 7.16.2 AstraZeneca Business Overview
  94. 7.16.3 AstraZeneca Peptide and Oligonucleotide Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 AstraZeneca Peptide and Oligonucleotide Drugs Product Portfolio
  96. 7.16.5 AstraZeneca Recent Developments
  97. 7.17 Asahi Kasei
  98. 7.17.1 Asahi Kasei Company Information
  99. 7.17.2 Asahi Kasei Business Overview
  100. 7.17.3 Asahi Kasei Peptide and Oligonucleotide Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Asahi Kasei Peptide and Oligonucleotide Drugs Product Portfolio
  102. 7.17.5 Asahi Kasei Recent Developments
  103. 7.18 Alnylam
  104. 7.18.1 Alnylam Company Information
  105. 7.18.2 Alnylam Business Overview
  106. 7.18.3 Alnylam Peptide and Oligonucleotide Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Alnylam Peptide and Oligonucleotide Drugs Product Portfolio
  108. 7.18.5 Alnylam Recent Developments
8 North America
  1. 8.1 North America Peptide and Oligonucleotide Drugs Market Size by Type
  2. 8.1.1 North America Peptide and Oligonucleotide Drugs Revenue by Type (2021-2032)
  3. 8.1.2 North America Peptide and Oligonucleotide Drugs Sales by Type (2021-2032)
  4. 8.1.3 North America Peptide and Oligonucleotide Drugs Price by Type (2021-2032)
  5. 8.2 North America Peptide and Oligonucleotide Drugs Market Size by Application
  6. 8.2.1 North America Peptide and Oligonucleotide Drugs Revenue by Application (2021-2032)
  7. 8.2.2 North America Peptide and Oligonucleotide Drugs Sales by Application (2021-2032)
  8. 8.2.3 North America Peptide and Oligonucleotide Drugs Price by Application (2021-2032)
  9. 8.3 North America Peptide and Oligonucleotide Drugs Market Size by Country
  10. 8.3.1 North America Peptide and Oligonucleotide Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Peptide and Oligonucleotide Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Peptide and Oligonucleotide Drugs Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Peptide and Oligonucleotide Drugs Market Size by Type
  2. 9.1.1 Europe Peptide and Oligonucleotide Drugs Revenue by Type (2021-2032)
  3. 9.1.2 Europe Peptide and Oligonucleotide Drugs Sales by Type (2021-2032)
  4. 9.1.3 Europe Peptide and Oligonucleotide Drugs Price by Type (2021-2032)
  5. 9.2 Europe Peptide and Oligonucleotide Drugs Market Size by Application
  6. 9.2.1 Europe Peptide and Oligonucleotide Drugs Revenue by Application (2021-2032)
  7. 9.2.2 Europe Peptide and Oligonucleotide Drugs Sales by Application (2021-2032)
  8. 9.2.3 Europe Peptide and Oligonucleotide Drugs Price by Application (2021-2032)
  9. 9.3 Europe Peptide and Oligonucleotide Drugs Market Size by Country
  10. 9.3.1 Europe Peptide and Oligonucleotide Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Peptide and Oligonucleotide Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Peptide and Oligonucleotide Drugs Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Peptide and Oligonucleotide Drugs Market Size by Type
  2. 10.1.1 China Peptide and Oligonucleotide Drugs Revenue by Type (2021-2032)
  3. 10.1.2 China Peptide and Oligonucleotide Drugs Sales by Type (2021-2032)
  4. 10.1.3 China Peptide and Oligonucleotide Drugs Price by Type (2021-2032)
  5. 10.2 China Peptide and Oligonucleotide Drugs Market Size by Application
  6. 10.2.1 China Peptide and Oligonucleotide Drugs Revenue by Application (2021-2032)
  7. 10.2.2 China Peptide and Oligonucleotide Drugs Sales by Application (2021-2032)
  8. 10.2.3 China Peptide and Oligonucleotide Drugs Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Peptide and Oligonucleotide Drugs Market Size by Type
  2. 11.1.1 Asia Peptide and Oligonucleotide Drugs Revenue by Type (2021-2032)
  3. 11.1.2 Asia Peptide and Oligonucleotide Drugs Sales by Type (2021-2032)
  4. 11.1.3 Asia Peptide and Oligonucleotide Drugs Price by Type (2021-2032)
  5. 11.2 Asia Peptide and Oligonucleotide Drugs Market Size by Application
  6. 11.2.1 Asia Peptide and Oligonucleotide Drugs Revenue by Application (2021-2032)
  7. 11.2.2 Asia Peptide and Oligonucleotide Drugs Sales by Application (2021-2032)
  8. 11.2.3 Asia Peptide and Oligonucleotide Drugs Price by Application (2021-2032)
  9. 11.3 Asia Peptide and Oligonucleotide Drugs Market Size by Country
  10. 11.3.1 Asia Peptide and Oligonucleotide Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Peptide and Oligonucleotide Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Peptide and Oligonucleotide Drugs Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Peptide and Oligonucleotide Drugs Market Size by Type
  2. 12.1.1 SAMEA Peptide and Oligonucleotide Drugs Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Peptide and Oligonucleotide Drugs Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Peptide and Oligonucleotide Drugs Price by Type (2021-2032)
  5. 12.2 SAMEA Peptide and Oligonucleotide Drugs Market Size by Application
  6. 12.2.1 SAMEA Peptide and Oligonucleotide Drugs Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Peptide and Oligonucleotide Drugs Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Peptide and Oligonucleotide Drugs Price by Application (2021-2032)
  9. 12.3 SAMEA Peptide and Oligonucleotide Drugs Market Size by Country
  10. 12.3.1 SAMEA Peptide and Oligonucleotide Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Peptide and Oligonucleotide Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Peptide and Oligonucleotide Drugs Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Peptide and Oligonucleotide Drugs Value Chain Analysis
  2. 13.1.1 Peptide and Oligonucleotide Drugs Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Peptide and Oligonucleotide Drugs Production Mode & Process
  6. 13.2 Peptide and Oligonucleotide Drugs Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Peptide and Oligonucleotide Drugs Distributors
  9. 13.2.3 Peptide and Oligonucleotide Drugs Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst